RESULTS	Although escalated dose results were favourable , no statistically significant differences were seen between the randomised groups ; PSA control ( hazard ratio ( HR ) : 0.77 ( 95 % confidence interval ( CI ) : 0.47-1 .26 ) ) , development of CRPC ( HR : 0.81 ( 95 % CI : 0.40-1 .65 ) ) , PC-specific survival ( HR : 0.59 ( 95 % CI :0.23 -1.49 ) ) and OS ( HR : 0.81 ( 95 % CI : 0.47-1 .40 ) ) .\